These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23606532)

  • 21. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms.
    Sanada M; Suzuki T; Shih LY; Otsu M; Kato M; Yamazaki S; Tamura A; Honda H; Sakata-Yanagimoto M; Kumano K; Oda H; Yamagata T; Takita J; Gotoh N; Nakazaki K; Kawamata N; Onodera M; Nobuyoshi M; Hayashi Y; Harada H; Kurokawa M; Chiba S; Mori H; Ozawa K; Omine M; Hirai H; Nakauchi H; Koeffler HP; Ogawa S
    Nature; 2009 Aug; 460(7257):904-8. PubMed ID: 19620960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
    Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
    Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
    Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
    Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. O-GlcNAcylation-inducing treatments inhibit estrogen receptor α expression and confer resistance to 4-OH-tamoxifen in human breast cancer-derived MCF-7 cells.
    Kanwal S; Fardini Y; Pagesy P; N'tumba-Byn T; Pierre-Eugène C; Masson E; Hampe C; Issad T
    PLoS One; 2013; 8(7):e69150. PubMed ID: 23935944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exosomes Mediated Transfer of Circ_UBE2D2 Enhances the Resistance of Breast Cancer to Tamoxifen by Binding to MiR-200a-3p.
    Hu K; Liu X; Li Y; Li Q; Xu Y; Zeng W; Zhong G; Yu C
    Med Sci Monit; 2020 Aug; 26():e922253. PubMed ID: 32756532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
    Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
    Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High IKKα expression is associated with reduced time to recurrence and cancer specific survival in oestrogen receptor (ER)-positive breast cancer.
    Bennett L; Quinn J; McCall P; Mallon EA; Horgan PG; McMillan DC; Paul A; Edwards J
    Int J Cancer; 2017 Apr; 140(7):1633-1644. PubMed ID: 28006839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cbl negatively regulates erythropoietin-induced growth and survival signaling through the proteasomal degradation of Src kinase.
    Shintani T; Ohara-Waki F; Kitanaka A; Tanaka T; Kubota Y
    Blood Cells Mol Dis; 2014 Dec; 53(4):211-8. PubMed ID: 25084697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein-tyrosine phosphatase alpha acts as an upstream regulator of Fyn signaling to promote oligodendrocyte differentiation and myelination.
    Wang PS; Wang J; Xiao ZC; Pallen CJ
    J Biol Chem; 2009 Nov; 284(48):33692-702. PubMed ID: 19812040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
    Truitt L; Freywald T; DeCoteau J; Sharfe N; Freywald A
    Cancer Res; 2010 Feb; 70(3):1141-53. PubMed ID: 20086179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppressed expression of Cbl-b by NF-κB mediates icotinib resistance in EGFR-mutant non-small-cell lung cancer.
    Zhang T; Zheng C; Hou K; Wang J; Zhang Y; Fan Y; Zhao H; Qu X; Liu Y; Kang J; Che X; Hu X
    Cell Biol Int; 2019 Feb; 43(2):98-107. PubMed ID: 29972257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Luminal breast cancer cell lines overexpressing ZNF703 are resistant to tamoxifen through activation of Akt/mTOR signaling.
    Zhang X; Mu X; Huang O; Xie Z; Jiang M; Geng M; Shen K
    PLoS One; 2013; 8(8):e72053. PubMed ID: 23991038
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism.
    Goodman CR; Sato T; Peck AR; Girondo MA; Yang N; Liu C; Yanac AF; Kovatich AJ; Hooke JA; Shriver CD; Mitchell EP; Hyslop T; Rui H
    Oncogene; 2016 Mar; 35(11):1373-85. PubMed ID: 26096934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UBASH3B/Sts-1-CBL axis regulates myeloid proliferation in human preleukemia induced by AML1-ETO.
    Goyama S; Schibler J; Gasilina A; Shrestha M; Lin S; Link KA; Chen J; Whitman SP; Bloomfield CD; Nicolet D; Assi SA; Ptasinska A; Heidenreich O; Bonifer C; Kitamura T; Nassar NN; Mulloy JC
    Leukemia; 2016 Mar; 30(3):728-39. PubMed ID: 26449661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated CRB3 expression suppresses breast cancer stemness by inhibiting β-catenin signalling to restore tamoxifen sensitivity.
    Li P; Feng C; Chen H; Jiang Y; Cao F; Liu J; Liu P
    J Cell Mol Med; 2018 Jul; 22(7):3423-3433. PubMed ID: 29602199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
    Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapamycin enhances the sensitivity of ER‑positive breast cancer cells to tamoxifen by upregulating p73 expression.
    Zhu L; Li XX; Shi L; Wu J; Qian JY; Xia TS; Zhou WB; Sun X; Zhou XJ; Wei JF; Ding Q
    Oncol Rep; 2019 Jan; 41(1):455-464. PubMed ID: 30542717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.
    Prud'homme GJ; Glinka Y; Toulina A; Ace O; Subramaniam V; Jothy S
    PLoS One; 2010 Nov; 5(11):e13831. PubMed ID: 21072210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.